General
Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended to Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer
PFL-241/STX-241 is a highly selective, and potentially best-in-class fourth generation epidermal growth factor receptor (“EGFR”) inhibitor One of two EGFR programs being developed with Scorpion Therapeutics CASTRES, France & BOSTON–(BUSINESS WIRE)– Pierre Fabre Laboratories, a global player in
Read MoreGeneral
Scorpion Therapeutics Presents Initial Clinical Data from Its Phase 1/2 Trial of STX-478 Demonstrating Potentially Best-in-Class Mutant-Selective PI3Kα Inhibition for the Treatment of Advanced Solid Tumors at ESMO Congress 2024
— STX-478 is active in multiple solid tumor types with both PI3K α kinase and helical domain mutations, achieving a monotherapy overall response rate (ORR) of 23% in breast cancer and 21% in all tumors — — Tumor reductions seen in 72% of patients as a monotherapy, with mutant PIK3CA circulating
Read MoreGeneral
Scorpion Therapeutics to Present STX-478 Initial Phase 1/2 Data at ESMO Congress 2024
BOSTON, Mass. – August 19, 2024 – Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, today announced that it was selected to present initial, first-in-human
Read More